Nagi Bioscience, focussing on laboratory technologies for alternative model organisms research, launched its Priority Access Program. With a focus on research applications in oncology, neurodegenerative diseases, aging and age-related conditions, and toxicology, SydLab One is set to facilitate and accelerate the ground-breaking research projects of the five participating laboratories.
The innovative SydLab One platform revolutionizes C. elegans experimentation, automating the entire process through a seamless integration of microfluidics, robotics, optics, and AI algorithms in just a single benchtop device. The five participating laboratories have been extensively recognized for their leadership in C. elegans research and in their respective application fields. They will be the first academic laboratories to integrate SydLab One into their research facilities. Their feedback will be instrumental in refining the platform for broader applications, helping to shape the future of automated, standardized and alternative biological research, drug candidate discovery and safety assessment.
Starting the installations in September 2024, SydLab One will be used in each of the participants facilities where it will enable researchers to conduct high-throughput and precise experiments with unprecedented efficiency, reliability, and reproducibility during a six-months period. “We are thrilled and honored to see our technology being adopted in an increasing number of research projects and centers, including some of the most prestigious laboratories in the world,” said Matteo Cornaglia, PhD, CEO and co-founder of Nagi Bioscience. “The SydLab platform is the culmination of over 10 years of multidisciplinary research and development, and it is fascinating to witness its potential in accelerating scientific discoveries in critical medical fields, such as neurodegenerative and age-related diseases, and beyond.”
C. elegans is a model organism widely used to understand biological processes and present in academic and industrial R&D laboratories for more than sixty years. With the launch of the Priory Access Program, Nagi Bioscience is ushering in a new era of automation in C. elegans research.
(Press release / SK)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines